rubió



Founded
1968

Location
Castellbisbal, Barcelona, Spain

Main Focus
CNS, Nephrology, Urology, Cardiovascular, Gastroenterology, Rheumatology/ Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubió
For more than 55 years Rubió, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Rubió's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnering Strategy
Rubió has established a strong network of partnerships through in and out activities and commercial distribution agreements. Rubió has been in the export business since 1982 and has alliances in over 70 countries. Rubió is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubió, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
www.laboratoriosrubio.com

Contact:
export@labrubio.com

07/2026

Brivaracetam

Modified Release Film-Coated Tablets



General Information

Brand:	Brivaracetam Rubió
API:	Brivaracetam.
Main presentations:	50/100/150/200mg 30 modified release film-coated tablets.

Indications

- Epilepsy.
- It is used in adults, adolescents and children from 2 years of age.
- It is used to treat a type of epilepsy that has partial seizures with or without a secondary generalization. Partial seizures are fits that start by only affecting one side of the brain. These partial seizures can spread and extend to larger areas on both sides of the brain – this is called a 'secondary generalization'.

  This medicine lowers the number of fits (seizures) the patient has.
- It is used together with other medicines for epilepsy.

Advantages

Instead of using 2 tablets per day with the modified release presentation with one tablet is enough.

Registration and Marketing Authorization

- CTD with BE with Briviact® for Q1 2029.

Deal Design

- We are looking for Distributors and/or Licensing Partners having a relevant sales structure in Central Nervous System (CNS) diseases to do a proper product promotion.
- Deal design consisting on a Supply & Distribution and/or Licensing & Supply Agreement to market the Finished Product manufactured by Laboratorios Rubió, S.A. in agreed countries.
- We are searching for the best Partners to develop trustful, fruitful and long-term business partnerships.